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Abstract
Background
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis which typically begins in early
adulthood and impacts on healthcare resource utilisation and the ability to work. Previous
studies examining the cost of AS have relied on patient-reported questionnaires based on
recall. This study uses a combination of patient-reported and linked-routine data to examine
the cost of AS in Wales, UK.
Methods
Participants in an existing AS cohort study (n = 570) completed questionnaires regarding
work status, out-of-pocket expenses, visits to health professionals and disease severity.
Participants gave consent for their data to be linked to routine primary and secondary care
clinical datasets. Health resource costs were calculated using a bottom-up micro-costing
approach. Human capital costs methods were used to estimate work productivity loss
costs, particularly relating to work and early retirement. Regression analyses were used to
account for age, gender, disease activity.
Results
The total cost of AS in the UK is estimated at £19016 per patient per year, calculated to
include GP attendance, administration costs and hospital costs derived from routine data
records, plus patient-reported non-NHS costs, out-of-pocket AS-related expenses, early
retirement, absenteeism, presenteeism and unpaid assistance costs. The majority of the
cost (>80%) was as a result of work-related costs.
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Conclusion
The major cost of AS is as a result of loss of working hours, early retirement and unpaid car-
er’s time. Therefore, much of AS costs are hidden and not easy to quantify. Functional
impairment is the main factor associated with increased cost of AS. Interventions which
keep people in work to retirement age and reduce functional impairment would have the
greatest impact on reducing costs of AS. The combination of patient-reported and linked
routine data significantly enhanced the health economic analysis and this methodology that
can be applied to other chronic conditions.
Introduction
Ankylosing Spondylitis (AS) is a chronic inflammatory arthritis characterised by spinal
involvement, with pain, stiffness and reduced range of movement. AS typically starts in the sec-
ond or third decades of life, and affects patients’ functioning and quality of life, with a signifi-
cant burden in terms of work impairment, early retirement, lifetime health and social care
resource utilisation [1–18].
A study investigating AS-related healthcare costs in three different European countries, esti-
mated costs at £2253/patient/year [17]. This study used patient-reported visits to healthcare
professionals to calculate costs. Separately the authors also examined work status and produc-
tivity costs in the same cohort and noted significant differences between countries. Costs ran-
ged between £406 and £1073 using the frictional cost method (employers’ perspective) and
£3080–£7561 using the human capital approach (patients’ perspective). These large differences
between countries makes it difficult to generalise work-related costs beyond the country of ori-
gin and suggests the majority of costs may be difficult to quantify. A study in the United King-
dom explored healthcare and productivity losses using patient-reported outcomes and the
human capital approach and found that on average, AS total costs over a period of three
months were £2802 (or £11208/person/year)(1). Healthcare-related costs contributed a small
proportion of the costs (just 15%) while work-related costs (unemployment, absenteeism and
reduced work productivity) accounted for the majority of AS-related costs. However, as with
previous studies these estimates are based entirely on patient-recall of healthcare visits, which
have well recognised limitations [19].
We have previously suggested that linked routinely collected healthcare data allows the
entire patient journey to be mapped more accurately, both retrospectively and prospectively,
thereby enhancing the data available for health economic analysis [20]. In this current study
we use linked patient-reported data and routinely collected medical record data to estimate the
total cost of AS in the UK, including healthcare resource utilisation, work productivity loss and
out-of pocket AS-related costs. Therefore, this paper and the novel methodology utilised
makes a significant contribution to the cost of illness literature in general as well as our under-
standing of the true costs of AS.
Materials and Methods
Ethics Statement
The study and amendments had full ethical approval from the London Multi-centre Research
Ethics Committee and was run in accord with Good Clinical Practice and the Declaration of
Helsinki. All participants gave written consent, including consent for data linkage.
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Participants and Healthcare System
Participants were part of a previously established population-based AS cohort created as part
of an Medical Research Council (MRC)/National Institute for Social Care and Health Research
(NISCHR) funded Patient Research Cohort Initiative, previously described [21]. The cohort
recruited 570 people with a diagnosis of AS confirmed by a rheumatologist, from across Wales
in the UK. Wales has the National Health Service (NHS) a universal healthcare system that
provides free medical care and is funded through taxes.
Patient-Reported Data
Participants were invited to complete questionnaires and return by post or online between
mid-2009 and mid-2010, which collected demographics, disease severity, work and activity
limitations, out-of-pocket expenses, transport to healthcare appointments and carer assistance.
Individuals were contacted up to a total of two times following initial contact before considered
as a non-responder.
Work Limitation Questionnaire (WLQ)
TheWLQ explores the degree of limitations experienced due to chronic health problems and
while work has not yet validated the WLQ is AS, the validity and reliability of the instrument
has been demonstrated in osteoarthritis [22]. Comprising 25 items, the WLQ invites respon-
dents to rate their level of difficulty or ability to perform work-specific demands. The items of
the WLQ are grouped into four scales; Time management, physical demands, mental-interper-
sonal and output demands scales. The scale scores range from 0 (limited none of the time) to
100 (limited all of the time). An algorithm converts the WLQ scale scores into an estimate of
productivity loss as a result of AS [23].
TheWork Productivity and Activity Impairment (WPAI)
TheWPAI Questionnaire is a quantitative measure that yields scores on absenteeism, presen-
teeism, work productivity loss and activity impairment that has been validated in AS [24]. The
six-itemWPAI investigates whether in current employment, the hours missed at worked due
to AS and other reasons, hours work and the degree to which AS affects productivity while
working or doing regular activities. Impairment scores are calculated and expressed as
impairment percentages, with higher numbers indicating greater impairment and less produc-
tivity [25].
Patient-Reported Healthcare Resource Use
Participants were asked to recall various AS-related events over the preceding 3 month period,
(visits to health professionals, transport, investigations performed, medication; prescribed and
over-the-counter (OTC), adaptations to the home/car, carer assistance, self-funded visits to
health professionals (e.g. private physiotherapy).
Measures of Disease Severity and Quality of Life
Disease-specific measures included the validated and routinely-used Bath Ankylosing Spondy-
litis Disease Activity Index (BASDAI) [26] and Bath Ankylosing Spondylitis Functional Index
(BASFI) [27]. Quality of life was assessed using the EuroQoL EQ-5D [28] and EQ-VAS for
Health Status from 0 (worst imaginable health state) to 100 (best imaginable health state).
Cost of AS in the UK
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Linked Routine Data
The Farr institute of Health Informatics Research comprises four nodes distributed across the
UK. One of the nodes, CIPHer (Centre for Improvement in Population Health through E-rec-
ords), brings together routine health data using the Secure Anonymised Information Linkage
(SAIL) databank [29, 30], which anonymously links a wide range of person-based data [31].
The range of complementary datasets include General Practice (GP) records, outpatient (OP),
inpatient (IP) and accident and emergency (A&E) department data containing data regarding
healthcare visits including reason for visit, medication administered and medical and surgical
procedures. Complete hospital data for Wales is available in the SAIL databank and presently,
195 GP practices out of 499 contribute to the SAIL databank, yielding a39% coverage for
Wales.
Public Health Resource Use
Healthcare costs were calculated using a bottom-up micro-costing approach, which estimates
the average cost of treatment patient/year using the unit costs combined with quantity of use.
The costs are reported at 2010 current prices, in terms of average cost patient/year and 95%
confidence intervals. The unit costs for healthcare use were obtained from a number of sources,
for instance, unit costs related to GP activities are taken from Unit Costs of Health and Social
Care by the Personal Social Services Research Unit (PSSRU) [32], where costs for a GP consul-
tation lasting 17.2 minutes and 11.7 minutes cost £53 and £36, respectively. GP visits were
assessed using patient-reported GP visits (questionnaires) and, where available, routine data
held in GP Read codes [33]. GP Read code data, does not necessarily indicate a personal con-
sultation or visit to the GP but may represent test results, letters, inputting data obtained from
other healthcare settings etc. Exploration of read codes indicated that whenever two or more
types of events were recorded in the codes on the same day (i.e. procedures, diagnosis or drugs)
this was likely to represent GP visit and counted as such, while a single event on a particular
day was not counted as a visit. Costs were attributed to that named GP event using the unit
costs for administration (S1 Table: Unit Costs). Patient-reported and routine data GP visits
were calculated separately and stratified by disease severity, function and age.
For prescription costs, the PSSRU 2010 reports average prescription cost issued from the
GP surgery, however in our cost calculation we have used a weighted average (based on usage)
of self-reported drugs prescribed for AS (painkillers, non-steroidal anti-inflammatory drugs
(NSAIDS), disease modifying anti-rheumatic drugs (DMARDs), and Anti-TNF agents)
obtained from the Prescription Cost Analysis (PCA) data for Wales 2010. We obtained a unit
cost of £60.60 for the AS-related drugs. Unit costs for outpatient attendances are taken from
NHS reference cost database (£137/attendance) which also costs diagnostic procedures such as
investigations, tests, drugs, devices as well as other costs that do not generate a separate health-
care resource group. Diagnostic imaging including plain x-rays, MRI and other scans were cal-
culated individually but are not reported separately due to their high volume and low cost.
Therapy services were also included where referral for treatment has been made by a clinician,
health professional or self-referral where the patient attends a discrete therapy clinic solely for
the purpose of receiving therapy treatment (S1 Table: Unit Costs).
Out-of-Pocket AS-Related Costs
The unit costs for transport used by the patients to attend healthcare facilities were obtained
from various web sources (e.g. AAMotoring cost 2010, UK railway travel cost compiled by the
Guardian [34]). Costs for OTC medications were calculated from the “prescription of Wales-
2010” dataset [35]. Patients’ out-of-pocket expenses also included: (i) ‘adjustment’ costs for
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making changes to their home or car, (ii) costs incurred for appliances and aids (iii) exercise-
related costs for AS and, (iv) one-off purchases AS-related purchases (S1 Table: Unit Costs).
Work Productivity Loss
Work-related costs were estimated using the human capital approach [36, 37]. The cost com-
ponents included early retirement, absenteeism (due to AS), presenteeism (due to AS) and
unpaid work by carers (including visits to healthcare facilities). Age and sex-specific average
daily wage rates obtained from the Office of National Statistics were used to value lost hours
due to AS (S2 Table: Hourly pay rate, gross (£) for all employee jobs in the United Kingdom at
2010 prices).
Statistical Analysis
The socio-demographics and clinical characteristics are presented using descriptive statistics
accompanied by the 95% confidence intervals and bootstrapped confidence intervals (1000
iterations), where applicable. Regression analysis was used to account for age, gender, disease
activity, functional impairment, quality of life and self-rated health status as correlates of cost.
All analyses were performed using STATA 12.
Factors Associated with Healthcare Costs
Patient-reported data and routine data were analysed separately. Comparison of routine with
patient-reported data were used to derive yearly estimates of healthcare use. Prescription esti-
mates used numbers of AS-related drugs. The average number of prescriptions is reported for
the 3 months recall period within the questionnaire and is also available in the routine data.
From routine data, 1 year and 5 year retrospective periods as well as 6 months prospectively
from the questionnaire completion date were collected and stratified by disease severity and
age.
Factors Associated with Work Productivity Loss
Multi-predictor maximum-likelihood logistic regression and Ordinary Least Squares (OLS)
regression models were fitted to the data to examine factors associated with AS-related work
costs. The factors examined included the continuous variables age, AS function index (BASFI),
and EQ5D score; and the binary variable, gender. In addition, nine cost indicators were consid-
ered as the dependent variables in the respective specifications. Logistic regression was used to
examine retirement due to AS (Yes/No) and requirement for unpaid assistance (Yes/No) as the
binary dependent variables. Seven multivariate OLS models were run where the dependent var-
iables was patient-reported productivity loss index, ability score, difficulty score, cost due to
absence from work, cost due to inefficient working hours at work (i.e. presenteeism), and the
retirement gap (i.e. the difference in years between the usual age of retirement and the actual
age at which the patients retired).
Results
Of 570 patients invited, 482 (85%) returned completed questionnaires. Hospital records were
available for all participants, while GP data was available for 150 participants at that time.
Respondents were 77% male; the mean age was 55.5 years (SD±15.9); mean BASDAI 43 and
BASFI 46.9. Mean disease duration was 19.8 years from diagnosis and 28.3 years from symp-
tom onset. These results are consistent with demographics for other AS cohorts. The respon-
dents’ demographic characteristics, stratified by employment status, are shown in Table 1.
Cost of AS in the UK
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Healthcare Resource Use
GP Visits and GP-Related Events
The average number of visits is reported for all participants, while GP events are reported only
for those patients whose information is present in the routine GP data (n = 150). Patients self-
reported a mean of 1.73 (95%CI: 1.39–208) GP visits over the previous 3 month period
Table 1. Demographic Characteristics of the study participants.
Characteristics Non-working
Patients
Working Patients
Number of patients 254 228
Number of Male (%) 193 (76) 167 (73)
Mean age in years (standard deviation) 59.74 (12.3) 46.73 (11.38)
Age<66 (% of patients) 169 (66.5) 215 (94.3)
Age retired (95% CI) 53.59 (52.14–
55.04)
Early retirement due to AS: No. of patients (% of patient) 173 (74)
Gap (years) between usual & actual age of retirement For
patients with early retirement due to AS
10.23 (8.59–
11.89)
Gap (years) between usual & actual age of retirement For
patients with early retirement not due to AS
7.18 (4.69–9.66)
Mean comparison t-test p-value 0.049
Mean hours/week actually worked (95% CI) (n) 35.1 (32.93–37.29)
n = 211
Mean hours/week absent due to AS (95% CI) (n)
For patients who were absent at least one hour 7.61 (4.1–11.13)
(n = 31)
For all patients in the job 1.15 (0.52–0.77)
(n = 206)
Mean hours/week absent due to other reason (95% CI) (n)
For patients who were absent at least one hour 13.26 (9.25–17.27)
(n = 35)
For all patients in the job 2.20 (1.27–3.12)
(n = 211)
Total hours/week working (95% CI) (n) 38.42 (36.52–40.32)
(n = 211)
Productivity loss in daily regular activity (mean score on a 0–10
scale, higher values indicate higher loss)
5.22 (4.88–5.58)
(n = 254)
3.28 (2.93–3.63)
(n = 225)
Productivity loss in on-the-job work (mean score on a 0–10
scale, higher values indicate higher loss)
2.19 (1.89–2.50)
(n = 223)
BASDAI: Mean (95% CI) 49.97 (46.79–
53.15)
38.56 (35.47–41.66)
BASFI: Mean (95% CI) 58.29 (54.85–
61.73)
35.13 (31.82–38.45)
Health Status: Mean (95% CI) 51.44 (48.51–
54.37)
66.12 (63.48–68.76)
EQ5D: Mean (95% CI) 0.47 (0.43–0.52) 0.68 (0.65–0.71)
AS Duration from diagnosis: Years (95% CI) 23.59 (21.37–
25.80)
15.60 (13.94–17.26)
AS Duration from first symptom Years (95% CI) 32.62 (30.47–
34.78)
23.67 (21.98–25.37)
doi:10.1371/journal.pone.0126105.t001
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compared to 1.35 (95%CI: 1.09–1.60) recorded in routine GP data for the same period. How-
ever, during the same 3 month recall period the routine GP data recorded a mean 6.11 (95%CI:
5.40–6.82) GP events for the participants, indicating substantial administrative costs even on
non-visit days (S3 Table: Average number of GP visits and events for the AS patients from
patient-derived data and routine data). The number of relevant prescriptions and GP proce-
dures are shown in S4 Table (Drugs and Medications prescribed for AS patients from routine
data) and S5 Table (GP Analysis: Healthcare resource procedures from routine data),
respectively.
GP and Prescription Costs
Two sets of cost estimates for GP utilisation and prescription costs are shown in Table 2 from
patient-reported data and routine data. For patient-reported data, GP attendance and prescrip-
tion costs were £1140 (95%CI: 935–1345) patient/year, mainly attributable to the use of
DMARDs and anti-TNF drugs. GP costs using linked routine data are £1067 (95%CI: 955–
1180) patient/year and include GP events (administration).
Routine data GP prescription costs were £395 compared to £899/patient/year for self-report
which can be attributed to the Welsh NHS funding model whereby anti-TNF agents are pre-
scribed by secondary-care (hospital-based rheumatology clinics) and not by GPs (who pre-
scribe all other medication).
Hospital Costs
Consistent with the GP data, patient-reported estimates for hospital attendances (IP day unit,
OP and A&E) were higher than those captured by routine data, and therefore associated with
higher costs (S6 Table: Patient-reported and routine data estimates of outpatient, inpatient,
and A&E attendance costs for AS patients (£/patient/year)). For both models,>95% of the hos-
pital attendance costs were attributed to OP clinics and IP (which include infusion and day
unit) episodes.
The average cost patient/year for consulting hospital-based healthcare professionals is £755,
mostly incurred for consulting rheumatologists (35%; £267) and physiotherapists (23%; £174)
(S7 Table: Distribution of healthcare cost stratified by disease severity, functional ability and
age). Cost estimates for secondary care investigations are also shown in S7 Table, with the
majority incurred for radiological investigations.
Total NHS Cost
Using the above data, the total costs (£/patient/year) to the NHS (GP, hospital, prescription
and investigation costs) were estimated at £3230 (95%CI 2666–3794) from patient-reported
data and £2343 (95%CI 2090–2596) using routine alone (Table 3).
Factors Associated with Public Healthcare Costs
Patients with higher disease activity (BASDAI40) and higher functional impairment
(BASFI40) incur significantly higher healthcare related costs than those with lower disease
activity and better function. This group were also more likely to overestimate the number of
self-reported GP visits (S3 Table). The marginal effects of function, disease activity and self-
reported Health Status on cost are reported in Table 4. The coefficients indicate that a 10 unit
increase in BASFI and BASDAI score are associated with £460 and £410 increases in the NHS
costs, respectively, while a 10 unit decrease in health status is associated with a £540 increase in
the NHS cost of AS.
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Out-of-Pocket AS-Related Costs
The mean AS-related, out-of-pocket expenses incurred by participants was £705/person/year
while one-off purchase expenses were £362/person/year (S8 Table: Out of Pocket AS-related
costs for the AS Patients (£/AS patient/year)). These costs include £58/person/year for trans-
port to healthcare appointments and £113/person/year for self-funded exercise outside of the
NHS.
Work Productivity Loss
Employment and Early Retirement
At the time of responding, 53% (254/482) of participants were not working (See Table 1). Of
the total 397 participants of working age (<65 years), 43% (169/397) were not working, which
entails a 57% labour force participation rate for AS patients. Of those no longer working, the
mean age of retirement was 53.6 years, with 74% citing AS as the main reason for early retire-
ment. On average, the AS patients retired 9.5 years earlier than the general population and
10.2 years earlier than the usual retirement age for their specific occupation.
Table 2. General Practitioner (GP) and prescription costs for AS.
Cost Items All Patient BASDAI Group BASFI Group Age
Mean (95% CI) Mean (95% CI) Mean (95% CI) (Mean 95% CI)
BASDAI < 40 BASDAI >40 BASFI < 40 BASFI >40 AGE < 50 AGE>50
(n = 400) (n = 188) (n = 212) (n = 175) (n = 225) (n = 150) (n = 250)
Panel A: Estimates from Questionnaire Data
(i) GP Visits 241 185 290 176 291 209 260
(213–269) (154–216) (247–334) (144–208) (250–333) (168–251) (223–297)
(ii) GP prescription cost 899 651 1119 500 1210 882 910
(698–1101) (421–883) (800–1438) (295–706) (894–1526) (585–1178) (640–1180)
Painkiller and NSAID 82 45 116 55 104 67 92
(75–90) (38–51) (105–127) (45–64) (94–114) (57–77) (82–102)
DMARDs and Anti-TNFs 817 607 1002 445 1106 815 818
(616–1018) (377–838) (683–1322) (240–651) (790–1421) (518–1112) (549–1088)
(iii) GP Travel costs 11 8.7 13.4 8 13.7 13.4 9.9
(7.7–14.7) (4.4–12.9) (8.1–18.8) (3.6–12.4) (8.5–18.8) (6.0–20.7) (6.5–13.3)
Total GP Cost (i + ii) 1140 837 1409 676 1501 1091 1170
(935–1345) (599–1074) (1087–1731) (464–888) (1182–1820) (790–1391) (894–1445)
Panel B: Estimates from Routine Data
All Patient BASDAI Group BASFI Group Age
BASDAI < 40 BASDAI >40 BASFI < 40 BASFI >40 AGE < 50 AGE>50
(n = 162) (n = 72) (n = 90) (n = 71) (n = 91) (n = 74) (n = 88)
(i) GP visits 183 132 225 123 231 156 207
(156–210) (100–163) (185–265) (94–152) (190–271) (118–193) (168–246)
(ii) GP events (Administration) 395 323 453 278 486 312 465
(352–438) (264–381) (394–512) (227–329) (427–545) (256–368) (405–524)
(iii) AS related Prescription 489 343 605 301 635 400 563
(419–559) (233–453) (522–689) (223–380) (536–734) (284–517) (481–646)
Total GP Cost (i + ii + iii) 1067 798 1283 703 1352 868 1235
(955–1180) (632–963) (1142–1424) (573–832) (1201–1502) (694–1042) (1095–1374)
doi:10.1371/journal.pone.0126105.t002
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Table 3. Total NHS cost for AS stratified by disease severity, functional ability and age (£/patient/year).
Cost Items All Patient BASDAI Group BASFI Group Age
Mean (95%
CI)
Mean (95% CI) Mean (95% CI) (Mean 95% CI)
BASDAI < 40 BASDAI
>40
BASDFI < 40 BASFI >40 AGE < 50 AGE>50
(n = 400) (n = 188) (n = 212) (n = 175) (n = 225) (n = 150) (n = 250)
Panel A: Estimates from Questionnaire Data
Total Cost NHS 3230 2384 3980 1994 4192 2811 3482
(2666–3794) (1582–3187) (3198–4763) (1208–2780) (3416–
4969)
(1855–
3768)
(2782–
4181)
Total Cost NHS (Lower bound
estimate)
2803 2039 3481 1714 3650 2510 2979
(2374–3232) (1468–2610) (2859–4103) (1160–2268) (3040–
4261)
(1792–
3228)
(2442–
3516)
Total Cost NHS (Upper bound
estimate)
3366 2494 4140 2083 4364 2909 364
(2757–3976) (1615–3373) (3302–4978) (1221–2945) (3531–5197) (1871–3946) (2887–4395)
Panel B: Estimates from Routine Data
Total Cost NHS 2343 1992 2654 1664 2871 1899 2609
(2090–2596) (1659–2326) (2282–3025) (1374–1954) (2495–
3247)
(1594–
2204)
(2251–
2967)
Total Cost NHS (Lower bound
estimate)
2049 1757 2308 1514 2465 1746 2231
(1871–2227) (1524–1990) (2046–2571) (1311–1717) (2202–2729) (1498–1994) (1989–2473)
Total Cost NHS (Upper bound
estimate)
2447 2076 2775 1717 3014 1953 2743
(2166–2727) (1706–2445) (2363–3188) (1396–2039) (2596–3432) (1625–2281) (2343–3143)
doi:10.1371/journal.pone.0126105.t003
Table 4. Marginal effect of BASFI, BASDAI, or Health Status on selected AS costs.
Covariates (Explanatory Variables) Dependent Variables
NHS Cost GP Cost OP Cost IP Cost Out of Pocket Expense
Panel A: Questionnaire Data
BASFI
46.04** 14.32** 14.75** 16.41* 12.3**
(CI: 26.1, 66.0) (CI: 7.1, 21.6) (CI: 8.20, 21.3) (CI: 0.04, 32.8) (CI: 4.9, 19.8)
BASDAI
40.64** 12.25** 16.33** 11.36** 14.1**
(CI: 18.2, 63.0) (CI: 5.9,19.3) (CI: 9.03, 23.6) (CI: -6.9, 29.6) (CI: 5.8, 22.4)
Health Status
-54.41** -17.13** -18.01** -18.07** -23.1**
(CI: -78.9, -30.0) (CI: -26.0, -8.3) (CI: -26.0, -10.0) (CI: -38.1, 2.0) (CI: -32.1, -14.2)
Panel B: Routine Data
BASFI
25.1** 10.7** 6.9** 9.7*
(CI: 11.5, 36.6) (CI: 7.1, 14.3) (CI: 3.7, 10.0) (CI: 2.3, 17.1)
BASDAI
26.3** 9.4** 5.2** 7.6
(CI: 11.0, 41.7) (CI: 5.2, 13.6) (CI: 1.6, 8.7) (CI: -0.8, 15.9)
Health Status
-42.7 -14.5** -9.6 -16.1**
(CI:- 59.4, -25.9) (CI: -19.0, -10.0) (CI: -13.4, -5.8) (CI: -25.2, -7.1)
Note: 95% confidence intervals for the coefficients are reported in the parentheses.
** implies that coefficients are significant at 1% level of significance (* implies 5% level). For each covariate, the regressions were run separately
controlling for age and sex. In the above table the marginal effects are therefore generated from running 15 specifications. Age was a significant
determinant for IP costs.
doi:10.1371/journal.pone.0126105.t004
Cost of AS in the UK
PLOSONE | DOI:10.1371/journal.pone.0126105 July 17, 2015 9 / 17
Absenteeism and Presenteeism
AS impacts both on the ability to attend work (absenteeism) and productivity while at work
(presenteeism). Participants reported the impact of AS on work performance (S9 Table: Impact
of AS on on-the-job performance due to physical and emotional problems). On average, partic-
ipants missed 3.5% (95%CI: 1.6–5.3, n = 197) of their work time (absenteeism) (Table 5). In
addition, they report 21.6% (95%CI: 18.6–24.7, n = 225) impairment of working level (presen-
teeism) and 26.1% (95%CI: 22.7–29.6, n = 197) overall work impairment due to AS.
Overall activity impairment due to ill-health was 33% for those in work (work and home
activities) and 52% for those not in work (home). Higher disease activity and functional
impairment were associated with significantly increased productivity and activity impairment
(Table 5).
Of employed participants, 13.6% (31/228) were absent from work during the past 7 days
due to AS and missed on average 7.6 (95%CI: 4.36–10.86) hours of work. For these participants
the self-reported mean productivity loss was 2.2 (CI: 1.9–2.5) indicating more than 20% loss of
productivity during the working hours. The productivity impact on daily regular household
tasks was 3.3 (i.e. more than 30% loss of productivity).
Work-Related Costs of AS
Using the age and sex specific national average daily wage rates (S2 Table: Hourly pay rate,
gross (£) for all employee jobs in the United Kingdom at 2010 prices), annual losses to earnings
per patient (not in paid work) were £23691 (95%CI: 21849–25534] under the human capital
approach (cost to patient). Spread across all AS patients in the cohort (working and not work-
ing), the early retirement cost of AS was estimated to be £8107 (95%CI: 6834–9380) year/
patient, and was significantly higher in those with BASDAI and BASFI40, but there were no
significant gender differences (Table 6).
Table 5. Work productivity and activity impairment outcomes as assessed by theWork Productivity Impairment Questionnaire.
Work Productivity Cost Components All Patients BASDAI Group BASFI Group
Working AS Patients (%; 95%CI; n)
Percent work time missed due to health 3.46 1.43 5.69 1.1 7.5
(CI: 1.6–5.3) (CI: 0.54–2.32) (CI: 1.92–9.46) (CI: 0.37–1.74) (CI: 2.7–12.2)
(n = 197) (n = 103) (n = 94) (n = 123) (n = 74)
Percent impairment while working due to health 21.6 11.7 33.4 13.9 33.5
(CI: 18.6–24.7) (CI: 9.2–14.3) (CI: 28.2–38.6) (CI: 11.5–16.3) (CI: 27.4–39.6)
(n = 225) (n = 122) (n = 103) (n = 136) (n = 89)
Percent overall work impairment due to health 26.1 15 38.3 16.2 42.7
(CI: 22.7–29.6) (CI: 12.0–18.0) (CI: 32.9–43.8) (CI: 13.6–18.8) (CI: 36.2–49.2)
(n = 197) (n = 103) (n = 94) (n = 123) (n = 74)
Percent activity impairment due to health 32.8 22.6 44.9 22.9 48
(CI: 29.3–36.3) (CI: 18.8–26.4) (CI: 39.6–50.1) (CI: 19.5–26.3) (CI: 42.1–53.8)
(n = 225) (n = 122) (n = 103) (n = 136) (n = 89)
AS Patients not at Work (%; 95%CI; n)
Productivity losses in daily regular activities
52.3 33.1 63.1 24.5 62.5
(CI: 49.1–56.0) (CI: 27.6–38.6) (CI: 59.5–66.7) (CI: 18.7–30.4) (CI: 59.3–65.7)
(n = 253) (n = 89) (n = 164) (n = 66) (n = 187)
doi:10.1371/journal.pone.0126105.t005
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The work-related AS costs for those patients in employment, was estimated to be £869 (95%
CI: £392–1346) due to lost hours at work (absenteeism) and £7241 (95%CI: 6163–8319) due to
the inefficient hours while working (presenteeism) per year per working patient. Spread across
the entire cohort (working and non-working), the estimates were £411 for absenteeism and
£3425 for presenteeism per year per AS patient (Table 6). Costs for absenteeism was associated
with higher disease activity and higher functional impairment, while presenteeism was mainly
associated with higher disease activity (Table 6 & S10 Table 10: Determinants of AS related
work productivity loss costs).
Factors Associated with Work Productivity Loss
Using logistic regression, early retirement due to illness was associated with functional
impairment, while using linear regression productivity loss (work and home) was associated
with younger age, increased functional impairment and lower quality of life (S10 Table). While
the costs due to absenteeism and presenteeism were associated with functional impairment,
neither was associated with gender. In addition, costs for absenteeism due to AS were associ-
ated with lower age, while costs for presenteeism were associated with lower quality of life.
Table 6. Work productivity loss cost estimates relating to early retirement, absenteeism, and presenteeism.
Cost Components
All Patients BASDAI Group BASFI Group Sex
Mean (95%
CI) (n)
Mean (95% CI) (n) Mean (95% CI) (n)
BASDAI < 40 BASDAI >40 BASFI < 40 BASFI >40 Female Males
Early retirement Cost(£)/year/AS
patients
8107 5765 9961 3740 11284 9459 7849
(CI: 6834–
9380)
(CI: 4106–
7423)
(CI: 8117–
11806)
(CI: 2313–
5168)
(CI: 9425–
13142)
(CI: 6928–
11990)
(CI: 6172–
9125)
(n = 482) (n = 213) (n = 269) (n = 203) (n = 279) (n = 122) (n = 360)
Absenteeism Cost(£)/year/AS patients
411 170 602 158 595 610 344
(CI: 183–
639)
(CI: 55–286) (CI: 204–
1000)
(CI: 51–265) (CI: 209–
981)
(CI: 85–
1135)
(CI: 94–
593)
(n = 482) (n = 213) (n = 269) (n = 203) (n = 279) (n = 122) (n = 360)
Presenteeism (Cost(£)/year/AS patients)
3425 2300 4316 3259 3546 3387 3438
(CI: 2823–
4028)
(CI: 1695–
2905)
(CI: 3359–
5274)
(CI: 2524–
3994)
(CI: 2650–
4443)
(CI: 2232–
4542)
(CI: 2730–
4147)
(n = 482) (n = 213) (n = 269) (n = 203) (n = 279) (n = 122) (n = 360)
Presenteeism (Cost(£)/year/working
patients)
7241 3950 11165 4829 10872 6774 7412
(CI: 6163–
8319)
(CI: 3010–
4891)
(CI: 9336–
12993)
(CI: 3840–
5818)
(CI: 8808–
12936)
(CI: 4782–
8765)
(CI: 6121–
8703)
n = 228 (n = 124) (n = 104) (n = 137) (n = 91) (n = 61) (n = 167)
Total (Absenteeism + Presenteeism)
(Cost(£)/year/AS patients)
3836 2470 4918 3417 4141 3997 3782
(CI: 3131–
4542)
(CI: 1840–
3100)
(CI: 3769–
6068)
(CI: 2666–
4169)
(CI: 3049–
5234)
(CI: 2628–
5366)
(CI: 2955–
4609)
(n = 482) (n = 213) (n = 269) (n = 203) (n = 279) (n = 122) (n = 360)
Total (Absenteeism + Presenteeism)
(Cost(£)/year/working patients)
8110 4243 12721 5063 12697 7993 8153
(CI: 6825–
9395)
(CI: 3270–
5215)
(CI: 10434–
15009)
(CI: 4058–
6069)
(CI: 10100–
15294)
(CI: 5630–
10357)
(CI: 6612–
9694)
(n = 228) (n = 124) (n = 104) (n = 137) (n = 91) (n = 61) (n = 167)
doi:10.1371/journal.pone.0126105.t006
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Cost of Unpaid Assistance
Patients with chronic diseases often require significant assistance from unpaid carers (usually
family members) who may themselves incur costs as a result of this (e.g. time off work for
carer-related activities). AS patients required an average of 52 hours of unpaid care givers’ time
during a 3 month period, incurring costs of £1279 (95%CI 903–1655) and £2983 (95%CI
2105–3680) year/patient when estimated using the minimum and mean national wage, respec-
tively (S11 Table: Cost estimates of unpaid assistance). The cost incurred due to unpaid assis-
tance and accompaniment for visits to various healthcare facilities was £193 (95%CI 91–295)
year/patient at mean national wage. Men have less assistance from informal carers than
women (S11 Table: Cost estimates of unpaid assistance).
Total Combined Costs
From the data presented above, it is clear that neither patient-reported nor routine data costs
alone can accurately capture the full costs of AS. We therefore calculated total costs by combin-
ing the datasets that most accurately capture the real-life situation for AS in the UK. Using
these datasets, the total cost of AS is estimated to be in the region of £19016 (95%CI: 14854–
23149)/patient/year (Table 7). This is calculated using routine datasets for GP attendance visits
(as it appears that patient-reported visits are an overestimate), GP administration events (not
captured at all in patient-reported data) and hospital (outpatient, inpatient and A&E) costs
from routine data (as for GP visits), while patient-reported questionnaires were used for pre-
scription costs (as medications like anti-TNF are not captured in the GP dataset), and self-
funded non-NHS costs; out-of-pocket expenses, one-off purchase expense, cost of transport to
health professionals, early retirement, absenteeism and presenteeism (patient-reported) and
unpaid assistance costs.
Table 7. Combined total cost of AS (£/AS patient/year).
Cost items All Patient Mean (95% CI) (n = 400)
GP visits/attendance* 183 (156–210)
Prescription costs 899 (698–1101)
GP events (administration)* 395 (352–438)
Outpatient costs* 558 (469–646)
In-patient costs* (incl. day unit) 710 (503–917)
A&E visit costs* 8.1 (4.2–12.0)
Non-NHS therapies (self-funded) 61 (48–74)
Out of pocket expenses + one off purchase 1067 (668–1526)
Transport to health care professionals 16.3 (10.3–22.8)
Early retirement 8107 (6834–9380)
Absenteeism 411 (183–639)
Presenteeism 3425 (2823–4028)
Cost of unpaid assistance at mean wage 2983 (2015–3860)
Cost of unpaid assistance for health care visits at mean wage 193 (91–295)
Total cost £19,016 (14,854–23,149)
Note: *indicates costs calculated from routine datasets. Other costs are calculated from patient-reported
questionnaires.
doi:10.1371/journal.pone.0126105.t007
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Discussion
We examine the total costs associated with AS in the UK using a population based cohort to
capture linked routine and patient-reported data. We employed the human capital approach so
productivity costs are included and therefore costs are not underestimated, as may be the case
for the friction cost approach. We found that patients with AS incur significant costs as a result
of their condition. In particular, AS has a significant effect on the ability to work with 43% of
people of working age either unemployed or retired early, and70% citing AS as the cause.
We estimated that the total cost of AS is £19016/person/ year including NHS costs, patient
costs and society costs. However, the majority of the costs are due to early retirement, ineffi-
cient working and unpaid carers’ time. Therefore, much of the costs of AS are hidden and not
captured using traditional methods. The cost of AS varies greatly with function and age.
The combination of patient-reported and linked healthcare data used here offers the oppor-
tunity to capture the most accurate and comprehensive dataset for cost calculations. This
methodology has allowed us to demonstrate that patients appear to overestimate their NHS
health-care visits in comparison to routine GP and hospital administrative records for the
same period. Routine data also allows GP administration costs to be captured, which are not
available elsewhere. Therefore, linked routine data appears to be the most accurate in capturing
healthcare visits in our setting. In contrast, effective and expensive AS medications such as
TNF-inhibitors are prescribed in specialist secondary-care settings in the UK, and therefore
not captured in the current routine GP prescribing dataset (these may be available in free-text
fields to which we do not have access for reasons of data privacy). Therefore, patient-reported
data is vital for accurate records of medications in the absence of a comprehensive prescrip-
tions register. Recall is also less of an issue here as patients have written prescriptions from
their GPs and are unlikely to forget that they receive injectable TNF-inhibitors for their AS.
Thus, the novel combination of both patient and linked routine data provides the optimal
information for estimating AS-related healthcare costs.
Our findings are comparable with previous UK research which also found that 45% of those
of working age were unemployed, 20% were work impaired and there was 14.9% AS-related
absenteeism, missing 8.78 days over a three month period (1). Our study finds a cost at £3836
due to loss of work for employed people and £8107 due to early retirement which equates to
£11943 per year per patient. This compares with £2342 per 3 months or £9368 per year
reported by Rafia et al [1]. Thus, findings from both studies for work-related costs are very sim-
ilar and the small differences might be explained by a difference in number of people in work
in Wales compared to England and differences in the populations studied.
Another UK study utilising secondary care medical records in 2008 reported costs attribut-
able to IP (£382), OP (£306), physiotherapy (£598) and medication (£372)(9). Our equivalent
figures today would give IP (£710), OP (£558), physiotherapy (£174) and medication (£899).
Our data suggests that, compared to this earlier study, there is a trend for reduced physiother-
apy and increased OP and IP attendance and costs. This is consistent with our observations in
clinical practice, since the introduction of TNF-inhibitors prescribed for AS, which have
increased the requirement for specialist (rheumatology) hospital-based input and reduced the
need for physiotherapy, due to better outcomes. Our estimated patient-reported medication
costs were higher (£899) which reflects the introduction of expensive anti-TNF therapy (used
in 15% of our cohort, which is comparable to 20% in another UK study [38]) for the treatment
of AS since 2008 and the fact that we also captured primary care medication.
Our findings enhance existing evidence that impaired function and increased disease activ-
ity lead to significant increase in the cost of AS. Therefore, interventions that improve the
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function and work productivity of patients are likely to lead to the largest reduction in the costs
of AS which are dominated by work-related costs.
This study gives the most comprehensive examination of the cost of AS in the UK, ever.
However, as with all economic evaluations, there are some limitations. Questionnaires could be
completed via postal or electronic methods, as such the equivalence of data from the two differ-
ent formats may have been an issue [39]. However, care was taken to avoid any substantial
changes when migrating the paper questionnaire to electronic format in order to reduce
response bias.
Visits to GPs are difficult to accurately identify using routine data, while patients tend to
over-report visits to health professionals. Future work could obtain the attendance log at a sam-
ple of GP practices to develop algorithms which accurately identify GP visits. Although this
work is the most comprehensive published evaluation of the costs of AS in the UK, there are
nevertheless still some costs which are not captured. For example, prescriptions through sec-
ondary care are not captured using GP data and are not currently available for these patients,
however patient-reported prescriptions give a proxy to this cost. Similarly, hospital administra-
tion costs which are likely to be considerable due to the administration associated with biolog-
ics, are not currently available and as such, costs will be underestimated here. Cost analysis has
been calculated at 2010 prices and so today’s cost would be increased.
At the time of study, measures of psychological well-being were not available for analysis,
however, research has shown that depression is associated with employment, absenteeism and
presenteeism[40]].
We have produced the most comprehensive cost analysis of AS in the UK to-date, using
routinely collected data in conjunction with patient-reported data that allows the hidden costs,
such as presenteeism, absenteeism and early retirement when calculating work productivity
loss costs and the effect of disease severity on cost estimates for the condition. This methodol-
ogy can also be adapted to develop enhanced health-economic analyses for a range of chronic,
long-term conditions.
Conclusions
The total cost of AS in the UK at the time of this work is estimated to be £19,016 per person
per year and is significantly higher in patients with poor function. The major cost of AS is as a
result of inefficient working hours, early retirement and in unpaid carer’s time. Interventions
which can keep people in productive work until retirement age would have the greatest single
impact in reducing costs in AS.
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